0001193125-20-251141.txt : 20201023 0001193125-20-251141.hdr.sgml : 20201023 20200922144058 ACCESSION NUMBER: 0001193125-20-251141 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20200922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Prelude Therapeutics Inc CENTRAL INDEX KEY: 0001678660 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811384762 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 BUSINESS PHONE: (302) 547-3768 MAIL ADDRESS: STREET 1: 200 POWDER MILL ROAD CITY: WILMINGTON STATE: DE ZIP: 19803 FORMER COMPANY: FORMER CONFORMED NAME: Prelude Therapeutics Inc. DATE OF NAME CHANGE: 20160630 CORRESP 1 filename1.htm CORRESP

Prelude Therapeutics Incorporated

200 Powder Mill Road

Wilmington, Delaware 19803

September 22, 2020

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

 

Attention:

Jeffrey Gabor

Laura Crotty

Rolf Sundwall

Jeanne Baker

 

Re:

Prelude Therapeutics Incorporated Registration Statement on Form S-1 (File No. 333-248628) originally filed September 4, 2020, as amended, and corresponding Registration Statement on Form 8-A (File No. 001-39527) filed September 16, 2020.

Requested Date: September 24, 2020

Requested Time: 4:00 PM Eastern Time

Ladies and Gentlemen:

Prelude Therapeutics Incorporated (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to declare the above-captioned Registration Statements on Form S-1 and Form 8-A effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Robert A. Freedman or Julia Forbess, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

The Registrant requests that it be notified of such effectiveness by a telephone call to Mr. Freedman at (650) 335-7292 or, in his absence, Ms. Forbess at (415) 875-2420.

* * *

Sincerely,
PRELUDE THERAPEUTICS INCORPORATED
By:  

/s/ Krishna Vaddi, Ph.D.

  Krishna Vaddi, Ph.D.
  Chief Executive Officer

 

cc:

Krishna Vaddi, Ph.D., Chief Executive Officer

Prelude Therapeutics Incorporated

Effie Toshav, Esq.

Robert A. Freedman, Esq.

Fenwick & West LLP